RA Safety

KINERET has decades of well-documented safety data targeting IL-1–mediated autoinflammation in RA1

Safety was demonstrated in a high-risk RA population and shown to be well-tolerated in those with1:

  • Varying degrees of disease activity
  • Concurrent medications for RA
  • History of complicating conditions, including:
  • Asthma
  • Diabetes
  • Chronic obstructive pulmonary disease
  • Pneumonia
Two overlapping squares that are transparent

KINERET offers flexibility to enable better disease control

The 4- to 6-hour half-life of KINERET gives doctors the flexibility to stop and restart treatment as necessary.1,2

KINERET offers a well-tolerated treatment experience1,3

  • The most commonly reported adverse events were injection site reactions (ISRs)
  • Most ISRs were mild (72.6% mild, 24.1% moderate, 3.2% severe)
  • The most serious adverse reactions were serious infections and neutropenia, particularly when used in combination with TNF-blocking agents
A chart showing the adverse events observed in patients being treated with KINERET® (anakinra) 100 mg/day compared to placebo. Please review the Important Safety Information on this website

Additional safety information1

  • In KINERET-treated NOMID patients, the risk of a disease flare when discontinuing KINERET treatment should be weighed against the potential risk of continued treatment. Do not initiate KINERET in patients with active infections
  • Use in combination with TNF-blocking agents is not recommended
  • Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported
  • The impact of treatment with KINERET on active and/or chronic infections and the development of malignancies is not known
  • Live vaccines should not be given concurrently with KINERET
  • Neutrophil counts should be assessed prior to initiating KINERET treatment, and while receiving KINERET, monthly for 3 months, and thereafter quarterly for a period up to 1 year